- Home
- TLSI vs SGMT Comparison
TLSI vs SGMT Comparison
Compare TLSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- SGMT
- Stock Information
- Founded
- TLSI 2010
- SGMT 2006
- Country
- TLSI United States
- SGMT United States
- Employees
- TLSI N/A
- SGMT N/A
- Industry
- TLSI Medical Specialities
- SGMT
- Sector
- TLSI Health Care
- SGMT
- Exchange
- TLSI Nasdaq
- SGMT Nasdaq
- Market Cap
- TLSI 244.3M
- SGMT 238.7M
- IPO Year
- TLSI N/A
- SGMT 2023
- Fundamental
- Price
- TLSI $4.55
- SGMT $7.70
- Analyst Decision
- TLSI Strong Buy
- SGMT Strong Buy
- Analyst Count
- TLSI 4
- SGMT 8
- Target Price
- TLSI $11.13
- SGMT $26.88
- AVG Volume (30 Days)
- TLSI 128.4K
- SGMT 647.2K
- Earning Date
- TLSI 11-13-2025
- SGMT 11-13-2025
- Dividend Yield
- TLSI N/A
- SGMT N/A
- EPS Growth
- TLSI N/A
- SGMT N/A
- EPS
- TLSI N/A
- SGMT N/A
- Revenue
- TLSI $35,990,000.00
- SGMT N/A
- Revenue This Year
- TLSI $56.71
- SGMT N/A
- Revenue Next Year
- TLSI $52.25
- SGMT N/A
- P/E Ratio
- TLSI N/A
- SGMT N/A
- Revenue Growth
- TLSI 45.50
- SGMT N/A
- 52 Week Low
- TLSI $3.42
- SGMT $1.73
- 52 Week High
- TLSI $5.88
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- TLSI 37.64
- SGMT 48.74
- Support Level
- TLSI $4.50
- SGMT $8.05
- Resistance Level
- TLSI $4.80
- SGMT $8.62
- Average True Range (ATR)
- TLSI 0.22
- SGMT 0.64
- MACD
- TLSI -0.05
- SGMT -0.05
- Stochastic Oscillator
- TLSI 0.00
- SGMT 24.03
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.